Ranking Profile - Jounce Therapeutics Inc

Introduction

Jounce Therapeutics Inc (Jounce Therapeutics) is a clinical stage immunotherapy company. It develops therapies that enable the immune system to attack tumors. The company’s major pipeline products include Vopratelimab, an IgG1 monoclonal antibody that activates T cells through ICOS; JTX-8064, an LILRB2 inhibitor novel antibody; JTX-1484; target is LILRB4, pimivalimab target receptor is PD-1, GS-1811; target receptor is CCR8. Its discovery programs include LILRB1, treatment of myeloid and lymphoid cancers. Jounce offers services in the areas of tumor immunology, antibody discovery and optimization and integrated translational capabilities. The company has collaborations with the universities, general hospitals, and cancer centers. Jounce Therapeutics is headquartered in Cambridge, Massachusetts, the US.